Fulgent Genetics (NASDAQ:FLGT) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.46) by 26.09 percent. This is a 928.57 percent decrease over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $85.389 million which missed the analyst consensus estimate of $94.000 million by 9.16 percent. This is a 4.38 percent increase over sales of $81.803 million the same period last year.